Erector Spinae Plane Block in Post-herpetic Neuralgia

NCT04546334 NA COMPLETED

This randomized clinical study will be carried out on 72 patients admitted to the pain clinic in Tanta University Hospitals with post-herpetic neuralgia. Cases presenting to the Pain Clinic with acute pain due to postherpetic neuralgia in thoracic and/or lumbar dermatomes with numerical rating scale (NRS) of 6 or more and they will be randomly divided, using the closed envelop method, into three equal groups. Group A (24 patients): Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block Group B (24 patients): Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment. Group C (24 patients): Patients that will subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment. Primary outcome will be the efficacy of pain relief Secondary outcome will be the frequency of pain and the consumption of analgesics.

Details

Lead sponsor	Tanta University
Phase	NA
Status	COMPLETED
Enrolment	90
Start date	Sat Sep 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jun 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Postherpetic Neuralgia

Interventions

• Medical treatment
• Real Erector Spinae block
• Real Erector Spinae block with magnesium sulphate
• Sham Erector Spinae block

Countries

Egypt